11:51 AM EDT, 04/28/2025 (MT Newswires) -- Pacira BioSciences ( PCRX ) said Monday that two-year results from a Phase 1 study showed its gene therapy candidate PCRX-201 provided sustained improvements in pain, stiffness, and function in patients with knee osteoarthritis.

Patients who received corticosteroid pretreatment experienced greater reductions in pain and stiffness, the company said.

PCRX-201, which boosts production of an anti-inflammatory protein, was generally well tolerated, with mild to moderate joint swelling as the most common side effect.

Pacira is currently enrolling patients in a phase 2 study of PCRX-201 for knee osteoarthritis.

Shares of Pacira were up 2.7% in recent trading.

Price: 26.41, Change: +0.69, Percent Change: +2.68